ORIC Pharmaceuticals opened lower at $8.77, compared with its previous close of $9.00. In the last trading session, the stock traded between $8.45 and $8.86. It showed a downward intraday trend.
An investment of $100 made 5 years ago in ORIC Pharmaceuticals is now worth
$ 47.83
Resulting in a loss of
$ 52.17 (52.17%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
$-0.52 (-5.78%)
Day High
$8.86
Day Low
$8.45
Day Open
$8.77
Prev Close
$9.00
Volume
9,02,726
1W Return
-9.30%
1M Return
-28.21%
3M Return
-38.25%
6M Return
-5.67%
1Y Return
-34.16%
Market Cap ($ Mn)
879
PE Ratio
-
PB Ratio
3.60
PEG Ratio
-
ROE
-41.02%
ROCE
-40.39%
EPS (TTM)
$-0.40
1 Week
-9.30%
1 Month
-28.21%
3 Months
-38.25%
6 Months
-5.67%
9 Months
-16.86%
ORIC Pharmaceuticals grants 14,800 options to new non-executive employee
ORIC Pharmaceuticals granted 14,800 stock options and 2,400 RSUs to one new employee. Grants were made on November 2, 2026, under the 2022 Inducement Equity Incentive Plan. Options vest with a 25% one-year cliff followed by monthly vesting for 36 months. RSUs vest in three equal annual installments over three years. Awards comply with Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.
6 days agoJP Morgan raises ORIC Pharmaceuticals price target to $26
JP Morgan raised ORIC Pharmaceuticals' price target to $26. Previous price target was set at $23. Analyst Anupam Rama maintained an Overweight rating.
29 days agoORIC Pharmaceuticals signs deal with Cancer Research UK for ORIC-259
ORIC Pharmaceuticals enters agreement with Cancer Research UK for ORIC-259. Cancer Research UK to fully fund CTA-enabling studies and Phase 1/2 trials. ORIC retains exclusive option to reacquire rights after Phase 1/2 data. ORIC-259 targets CIP2A, a previously undruggable protein in cancer.
1mo agoORIC Pharmaceuticals grants equity inducement to two new employees
Granted 39,200 stock options and 6,400 RSUs to two new hires. Awards serve as material inducement under Nasdaq Rule 5635(c)(4). Options vest 25% at year one then monthly; RSUs vest annually. Exercise price set at September 1, 2026 closing price. Recipients joined the firm in August 2026.
2mo agoORIC Pharmaceuticals grants 145,950 equity units to five new hires
ORIC Pharmaceuticals granted 125,400 stock options and 20,550 RSUs to five new employees on August 3, 2026. The awards were approved by the Compensation Committee under Nasdaq Rule 5635(c)(4) as a material inducement to employment. Vesting schedules range from one to four years, aligning employee incentives with the company's long-term clinical development goals for its oncology pipeline.
3mo agoORIC Pharmaceuticals Q2 Results: Net loss widens to $41.5 million
ORIC Pharmaceuticals posted a Q2 2026 net loss of $41.5 million, driven by higher R&D costs linked to its new Phase 3 trial. Cash reserves stand at $387.6 million, supporting operations through 2028. Key milestones include the start of the Himalayas-1 trial and a drug supply deal with Bayer.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in ORIC Pharmaceuticals is now worth
$ 47.83
Resulting in a loss of
$ 52.17 (52.17%)
Note: Past profits do not guarantee future returns.
